Global Urinary Tract Cancer Market
Global Urinary Tract Cancer Market

Urinary Tract Cancer Comprehensive Study by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Others), Diagnosis Technique (Cytoscopy, Urine Analyses, Biopsy, Imaging Test (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) Scan, Bone Scan, X-Ray Scan, Ultrasound)), Treatment Procedure (Biological Therapy (Synthetic Version of an Immune System Protein, Immune-Stimulating Bacterium), Surgical Treatment (Radical Cystectomy, Transurethral Resection (TUR), Others), Radiation Therapy, Chemotherapy, Others), End User (Hospitals, Clinics, Research Centers, Others) Players and Region - Global Market Outlook to 2024

Urinary Tract Cancer Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

May 2019 Edition 216 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Urinary Tract Cancer Market Scope
Growing bladder cancer cases and technological developments in treatment will help to fuel global urinary tract cancer market. Urinary tract cancer is usually called as bladder cancer. Urinary tract cancer is referred to as an uncontrolled growth of cells in the urinary tract. The urine tract cancer is primarily detected among the generic population, smokers, workers in chemical industries and people with prolonged urine infections.

The market study is being classified by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma and Others) and major geographies with country level break-up.

Leading global players are focusing on strategic partnerships to improve their products and services. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Urinary Tract Cancer market throughout the predicted period.

Spectrum pharmaceuticals (United States), Boehringer Ingelheim GmbH (Germany), Novartis AG (Switzerland), IkerChem S.L. (Spain), Bayer AG (Germany), Bristol-Myers Squibb Company (United States), Genzyme Corporation (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Medical Enzymes AG (Germany) and Amgen Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are GlaxoSmithKline plc (United Kingdom), Pfizer Inc. (United States), Shionogi & Co., Ltd. (Japan) and Kyowa Hakko Kirin Co., Ltd. (Japan).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Urinary Tract Cancer market by Type, Application and Region.

On the basis of geography, the market of Urinary Tract Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Diagnosis Technique, the sub-segment i.e. Cytoscopy will boost the Urinary Tract Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Procedure, the sub-segment i.e. Biological Therapy [Synthetic Version of an Immune System Protein, Immune-Stimulating Bacterium] will boost the Urinary Tract Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Urinary Tract Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.


On 12th April 2019, The U.S. Food and Drug Administration has granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. Patients should be selected for therapy with Balversa using an FDA-approved companion diagnostic device.

Market Trend
  • High Demand Due To Advancement in Medicine
  • Growing Demand Due To Introduction of New Diagnosis Tools
  • High Demand Due To Rigorous Research Activities by Governments and Academics

Market Drivers
  • Rising In the Number of Smokers around the World
  • Upsurge in the Geriatric Population
  • Growing Prevalence of a Sedentary Lifestyle

Opportunities
  • Clinical Trial Review of the Therapeutics to Treat Urinary Tract Cancer
  • High Adoption of Advanced Healthcare Services & Technology in Developing Nations

Restraints
  • The Rise in the Use of Generic Drugs
  • Asymptomatic Nature of the Diseases

Challenges
  • High Costs of Therapies, And Inaccurate and Unaffordable Diagnosis


Key Target Audience
Bladder Cancer Drug Companies, Suppliers and Distributors of Drugs, Healthcare Service Providers, Research and Consulting Firms, Medical Research Institutes, Venture Capitalists, Community Centers and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Urothelial Carcinoma
  • Squamous Cell Carcinoma
  • Adenocarcinoma
  • Others
By Diagnosis Technique
  • Cytoscopy
  • Urine Analyses
  • Biopsy
  • Imaging Test [Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) Scan, Bone Scan, X-Ray Scan, Ultrasound]

By Treatment Procedure
  • Biological Therapy [Synthetic Version of an Immune System Protein, Immune-Stimulating Bacterium]
  • Surgical Treatment [Radical Cystectomy, Transurethral Resection (TUR), Others]
  • Radiation Therapy
  • Chemotherapy
  • Others

By End User
  • Hospitals
  • Clinics
  • Research Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising In the Number of Smokers around the World
      • 3.2.2. Upsurge in the Geriatric Population
      • 3.2.3. Growing Prevalence of a Sedentary Lifestyle
    • 3.3. Market Challenges
      • 3.3.1. High Costs of Therapies, And Inaccurate and Unaffordable Diagnosis
    • 3.4. Market Trends
      • 3.4.1. High Demand Due To Advancement in Medicine
      • 3.4.2. Growing Demand Due To Introduction of New Diagnosis Tools
      • 3.4.3. High Demand Due To Rigorous Research Activities by Governments and Academics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Urinary Tract Cancer, by Type, Diagnosis Technique, Treatment Procedure, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Urinary Tract Cancer (Value)
      • 5.2.1. Global Urinary Tract Cancer by: Type (Value)
        • 5.2.1.1. Urothelial Carcinoma
        • 5.2.1.2. Squamous Cell Carcinoma
        • 5.2.1.3. Adenocarcinoma
        • 5.2.1.4. Others
      • 5.2.2. Global Urinary Tract Cancer by: Diagnosis Technique (Value)
        • 5.2.2.1. Cytoscopy
        • 5.2.2.2. Urine Analyses
        • 5.2.2.3. Biopsy
        • 5.2.2.4. Imaging Test [Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) Scan, Bone Scan, X-Ray Scan, Ultrasound]
      • 5.2.3. Global Urinary Tract Cancer by: Treatment Procedure (Value)
        • 5.2.3.1. Biological Therapy [Synthetic Version of an Immune System Protein, Immune-Stimulating Bacterium]
        • 5.2.3.2. Surgical Treatment [Radical Cystectomy, Transurethral Resection (TUR), Others]
        • 5.2.3.3. Radiation Therapy
        • 5.2.3.4. Chemotherapy
        • 5.2.3.5. Others
      • 5.2.4. Global Urinary Tract Cancer by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Research Centers
        • 5.2.4.4. Others
      • 5.2.5. Global Urinary Tract Cancer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Urinary Tract Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Spectrum pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim GmbH (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. IkerChem S.L. (Spain)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Genzyme Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Medical Enzymes AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Urinary Tract Cancer Sale, by Type, Diagnosis Technique, Treatment Procedure, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Urinary Tract Cancer (Value)
      • 7.2.1. Global Urinary Tract Cancer by: Type (Value)
        • 7.2.1.1. Urothelial Carcinoma
        • 7.2.1.2. Squamous Cell Carcinoma
        • 7.2.1.3. Adenocarcinoma
        • 7.2.1.4. Others
      • 7.2.2. Global Urinary Tract Cancer by: Diagnosis Technique (Value)
        • 7.2.2.1. Cytoscopy
        • 7.2.2.2. Urine Analyses
        • 7.2.2.3. Biopsy
        • 7.2.2.4. Imaging Test [Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) Scan, Bone Scan, X-Ray Scan, Ultrasound]
      • 7.2.3. Global Urinary Tract Cancer by: Treatment Procedure (Value)
        • 7.2.3.1. Biological Therapy [Synthetic Version of an Immune System Protein, Immune-Stimulating Bacterium]
        • 7.2.3.2. Surgical Treatment [Radical Cystectomy, Transurethral Resection (TUR), Others]
        • 7.2.3.3. Radiation Therapy
        • 7.2.3.4. Chemotherapy
        • 7.2.3.5. Others
      • 7.2.4. Global Urinary Tract Cancer by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Research Centers
        • 7.2.4.4. Others
      • 7.2.5. Global Urinary Tract Cancer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Urinary Tract Cancer: by Type(USD Million)
  • Table 2. Urinary Tract Cancer Urothelial Carcinoma , by Region USD Million (2013-2018)
  • Table 3. Urinary Tract Cancer Squamous Cell Carcinoma , by Region USD Million (2013-2018)
  • Table 4. Urinary Tract Cancer Adenocarcinoma , by Region USD Million (2013-2018)
  • Table 5. Urinary Tract Cancer Others , by Region USD Million (2013-2018)
  • Table 6. Urinary Tract Cancer: by Diagnosis Technique(USD Million)
  • Table 7. Urinary Tract Cancer Cytoscopy , by Region USD Million (2013-2018)
  • Table 8. Urinary Tract Cancer Urine Analyses , by Region USD Million (2013-2018)
  • Table 9. Urinary Tract Cancer Biopsy , by Region USD Million (2013-2018)
  • Table 10. Urinary Tract Cancer Imaging Test [Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) Scan, Bone Scan, X-Ray Scan, Ultrasound] , by Region USD Million (2013-2018)
  • Table 11. Urinary Tract Cancer: by Treatment Procedure(USD Million)
  • Table 12. Urinary Tract Cancer Biological Therapy [Synthetic Version of an Immune System Protein, Immune-Stimulating Bacterium] , by Region USD Million (2013-2018)
  • Table 13. Urinary Tract Cancer Surgical Treatment [Radical Cystectomy, Transurethral Resection (TUR), Others] , by Region USD Million (2013-2018)
  • Table 14. Urinary Tract Cancer Radiation Therapy , by Region USD Million (2013-2018)
  • Table 15. Urinary Tract Cancer Chemotherapy , by Region USD Million (2013-2018)
  • Table 16. Urinary Tract Cancer Others , by Region USD Million (2013-2018)
  • Table 17. Urinary Tract Cancer: by End User(USD Million)
  • Table 18. Urinary Tract Cancer Hospitals , by Region USD Million (2013-2018)
  • Table 19. Urinary Tract Cancer Clinics , by Region USD Million (2013-2018)
  • Table 20. Urinary Tract Cancer Research Centers , by Region USD Million (2013-2018)
  • Table 21. Urinary Tract Cancer Others , by Region USD Million (2013-2018)
  • Table 22. South America Urinary Tract Cancer, by Country USD Million (2013-2018)
  • Table 23. South America Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 24. South America Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 25. South America Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 26. South America Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 27. Brazil Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 28. Brazil Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 29. Brazil Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 30. Brazil Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 31. Argentina Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 32. Argentina Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 33. Argentina Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 34. Argentina Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 35. Rest of South America Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 36. Rest of South America Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 37. Rest of South America Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 38. Rest of South America Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 39. Asia Pacific Urinary Tract Cancer, by Country USD Million (2013-2018)
  • Table 40. Asia Pacific Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 41. Asia Pacific Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 42. Asia Pacific Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 43. Asia Pacific Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 44. China Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 45. China Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 46. China Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 47. China Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 48. Japan Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 49. Japan Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 50. Japan Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 51. Japan Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 52. India Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 53. India Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 54. India Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 55. India Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 56. South Korea Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 57. South Korea Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 58. South Korea Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 59. South Korea Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 60. Taiwan Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 61. Taiwan Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 62. Taiwan Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 63. Taiwan Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 64. Australia Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 65. Australia Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 66. Australia Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 67. Australia Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 68. Rest of Asia-Pacific Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 69. Rest of Asia-Pacific Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 70. Rest of Asia-Pacific Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 71. Rest of Asia-Pacific Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 72. Europe Urinary Tract Cancer, by Country USD Million (2013-2018)
  • Table 73. Europe Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 74. Europe Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 75. Europe Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 76. Europe Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 77. Germany Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 78. Germany Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 79. Germany Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 80. Germany Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 81. France Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 82. France Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 83. France Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 84. France Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 85. Italy Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 86. Italy Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 87. Italy Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 88. Italy Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 89. United Kingdom Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 90. United Kingdom Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 91. United Kingdom Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 92. United Kingdom Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 93. Netherlands Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 94. Netherlands Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 95. Netherlands Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 96. Netherlands Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 97. Rest of Europe Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 98. Rest of Europe Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 99. Rest of Europe Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 100. Rest of Europe Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 101. MEA Urinary Tract Cancer, by Country USD Million (2013-2018)
  • Table 102. MEA Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 103. MEA Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 104. MEA Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 105. MEA Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 106. Middle East Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 107. Middle East Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 108. Middle East Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 109. Middle East Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 110. Africa Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 111. Africa Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 112. Africa Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 113. Africa Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 114. North America Urinary Tract Cancer, by Country USD Million (2013-2018)
  • Table 115. North America Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 116. North America Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 117. North America Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 118. North America Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 119. United States Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 120. United States Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 121. United States Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 122. United States Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 123. Canada Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 124. Canada Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 125. Canada Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 126. Canada Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 127. Mexico Urinary Tract Cancer, by Type USD Million (2013-2018)
  • Table 128. Mexico Urinary Tract Cancer, by Diagnosis Technique USD Million (2013-2018)
  • Table 129. Mexico Urinary Tract Cancer, by Treatment Procedure USD Million (2013-2018)
  • Table 130. Mexico Urinary Tract Cancer, by End User USD Million (2013-2018)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Urinary Tract Cancer: by Type(USD Million)
  • Table 142. Urinary Tract Cancer Urothelial Carcinoma , by Region USD Million (2019-2024)
  • Table 143. Urinary Tract Cancer Squamous Cell Carcinoma , by Region USD Million (2019-2024)
  • Table 144. Urinary Tract Cancer Adenocarcinoma , by Region USD Million (2019-2024)
  • Table 145. Urinary Tract Cancer Others , by Region USD Million (2019-2024)
  • Table 146. Urinary Tract Cancer: by Diagnosis Technique(USD Million)
  • Table 147. Urinary Tract Cancer Cytoscopy , by Region USD Million (2019-2024)
  • Table 148. Urinary Tract Cancer Urine Analyses , by Region USD Million (2019-2024)
  • Table 149. Urinary Tract Cancer Biopsy , by Region USD Million (2019-2024)
  • Table 150. Urinary Tract Cancer Imaging Test [Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) Scan, Bone Scan, X-Ray Scan, Ultrasound] , by Region USD Million (2019-2024)
  • Table 151. Urinary Tract Cancer: by Treatment Procedure(USD Million)
  • Table 152. Urinary Tract Cancer Biological Therapy [Synthetic Version of an Immune System Protein, Immune-Stimulating Bacterium] , by Region USD Million (2019-2024)
  • Table 153. Urinary Tract Cancer Surgical Treatment [Radical Cystectomy, Transurethral Resection (TUR), Others] , by Region USD Million (2019-2024)
  • Table 154. Urinary Tract Cancer Radiation Therapy , by Region USD Million (2019-2024)
  • Table 155. Urinary Tract Cancer Chemotherapy , by Region USD Million (2019-2024)
  • Table 156. Urinary Tract Cancer Others , by Region USD Million (2019-2024)
  • Table 157. Urinary Tract Cancer: by End User(USD Million)
  • Table 158. Urinary Tract Cancer Hospitals , by Region USD Million (2019-2024)
  • Table 159. Urinary Tract Cancer Clinics , by Region USD Million (2019-2024)
  • Table 160. Urinary Tract Cancer Research Centers , by Region USD Million (2019-2024)
  • Table 161. Urinary Tract Cancer Others , by Region USD Million (2019-2024)
  • Table 162. South America Urinary Tract Cancer, by Country USD Million (2019-2024)
  • Table 163. South America Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 164. South America Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 165. South America Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 166. South America Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 167. Brazil Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 168. Brazil Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 169. Brazil Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 170. Brazil Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 171. Argentina Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 172. Argentina Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 173. Argentina Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 174. Argentina Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 175. Rest of South America Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 176. Rest of South America Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 177. Rest of South America Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 178. Rest of South America Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 179. Asia Pacific Urinary Tract Cancer, by Country USD Million (2019-2024)
  • Table 180. Asia Pacific Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 181. Asia Pacific Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 182. Asia Pacific Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 183. Asia Pacific Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 184. China Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 185. China Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 186. China Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 187. China Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 188. Japan Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 189. Japan Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 190. Japan Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 191. Japan Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 192. India Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 193. India Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 194. India Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 195. India Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 196. South Korea Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 197. South Korea Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 198. South Korea Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 199. South Korea Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 200. Taiwan Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 201. Taiwan Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 202. Taiwan Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 203. Taiwan Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 204. Australia Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 205. Australia Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 206. Australia Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 207. Australia Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 208. Rest of Asia-Pacific Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 209. Rest of Asia-Pacific Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 210. Rest of Asia-Pacific Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 211. Rest of Asia-Pacific Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 212. Europe Urinary Tract Cancer, by Country USD Million (2019-2024)
  • Table 213. Europe Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 214. Europe Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 215. Europe Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 216. Europe Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 217. Germany Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 218. Germany Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 219. Germany Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 220. Germany Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 221. France Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 222. France Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 223. France Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 224. France Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 225. Italy Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 226. Italy Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 227. Italy Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 228. Italy Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 229. United Kingdom Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 230. United Kingdom Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 231. United Kingdom Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 232. United Kingdom Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 233. Netherlands Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 234. Netherlands Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 235. Netherlands Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 236. Netherlands Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 237. Rest of Europe Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 238. Rest of Europe Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 239. Rest of Europe Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 240. Rest of Europe Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 241. MEA Urinary Tract Cancer, by Country USD Million (2019-2024)
  • Table 242. MEA Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 243. MEA Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 244. MEA Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 245. MEA Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 246. Middle East Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 247. Middle East Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 248. Middle East Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 249. Middle East Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 250. Africa Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 251. Africa Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 252. Africa Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 253. Africa Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 254. North America Urinary Tract Cancer, by Country USD Million (2019-2024)
  • Table 255. North America Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 256. North America Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 257. North America Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 258. North America Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 259. United States Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 260. United States Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 261. United States Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 262. United States Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 263. Canada Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 264. Canada Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 265. Canada Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 266. Canada Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 267. Mexico Urinary Tract Cancer, by Type USD Million (2019-2024)
  • Table 268. Mexico Urinary Tract Cancer, by Diagnosis Technique USD Million (2019-2024)
  • Table 269. Mexico Urinary Tract Cancer, by Treatment Procedure USD Million (2019-2024)
  • Table 270. Mexico Urinary Tract Cancer, by End User USD Million (2019-2024)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Urinary Tract Cancer: by Type USD Million (2013-2018)
  • Figure 5. Global Urinary Tract Cancer: by Diagnosis Technique USD Million (2013-2018)
  • Figure 6. Global Urinary Tract Cancer: by Treatment Procedure USD Million (2013-2018)
  • Figure 7. Global Urinary Tract Cancer: by End User USD Million (2013-2018)
  • Figure 8. South America Urinary Tract Cancer Share (%), by Country
  • Figure 9. Asia Pacific Urinary Tract Cancer Share (%), by Country
  • Figure 10. Europe Urinary Tract Cancer Share (%), by Country
  • Figure 11. MEA Urinary Tract Cancer Share (%), by Country
  • Figure 12. North America Urinary Tract Cancer Share (%), by Country
  • Figure 13. Global Urinary Tract Cancer share by Players 2018 (%)
  • Figure 14. Global Urinary Tract Cancer share by Players (Top 3) 2018(%)
  • Figure 15. Global Urinary Tract Cancer share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Spectrum pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Spectrum pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 19. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2018
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 23. IkerChem S.L. (Spain) Revenue, Net Income and Gross profit
  • Figure 24. IkerChem S.L. (Spain) Revenue: by Geography 2018
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 27. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 28. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2018
  • Figure 29. Genzyme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Genzyme Corporation (United States) Revenue: by Geography 2018
  • Figure 31. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2018
  • Figure 33. Medical Enzymes AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Medical Enzymes AG (Germany) Revenue: by Geography 2018
  • Figure 35. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amgen Inc. (United States) Revenue: by Geography 2018
  • Figure 37. Global Urinary Tract Cancer: by Type USD Million (2019-2024)
  • Figure 38. Global Urinary Tract Cancer: by Diagnosis Technique USD Million (2019-2024)
  • Figure 39. Global Urinary Tract Cancer: by Treatment Procedure USD Million (2019-2024)
  • Figure 40. Global Urinary Tract Cancer: by End User USD Million (2019-2024)
  • Figure 41. South America Urinary Tract Cancer Share (%), by Country
  • Figure 42. Asia Pacific Urinary Tract Cancer Share (%), by Country
  • Figure 43. Europe Urinary Tract Cancer Share (%), by Country
  • Figure 44. MEA Urinary Tract Cancer Share (%), by Country
  • Figure 45. North America Urinary Tract Cancer Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Spectrum pharmaceuticals (United States)
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis AG (Switzerland)
  • IkerChem S.L. (Spain)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (United States)
  • Genzyme Corporation (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Medical Enzymes AG (Germany)
  • Amgen Inc. (United States)
Additional players considered in the study are as follows:
GlaxoSmithKline plc (United Kingdom) , Pfizer Inc. (United States) , Shionogi & Co., Ltd. (Japan) , Kyowa Hakko Kirin Co., Ltd. (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation